TY - JOUR
T1 - The effects of the atypical antipsychotic asenapine in a strain-specific battery of tests for mania-like behaviors
AU - Ene, Hila M.
AU - Kara, Nirit Z.
AU - Einat, Haim
N1 - Publisher Copyright:
Copyright © 2015 Wolters Kluwer Health, Inc.
PY - 2015/7/22
Y1 - 2015/7/22
N2 - Asenapine is indicated for the treatment of schizophrenia and manic episodes in bipolar disorder (BPD). There is a paucity of information on the effects of asenapine in animal models of BPD, but such work is essential to discover its scope of effects and its mechanisms of therapeutic action. This study evaluated the effects of asenapine in a validated test battery for manic-like behaviors in Black Swiss mice. Male Black Swiss mice received asenapine at 0.03, 0.1, and 0.3 mg/kg twice daily for 7 days and were tested for spontaneous activity, sweet solution preference, forcedswim test, social interaction, and amphetamine-induced hyperactivity. Asenapine treatment resulted in dosedependent, clinically relevant plasma levels. Asenapine, at the 0.1 and 0.3 mg/kg doses, reduced activity, with the 0.3 mg/kg dose also resulting in increased time in the center of an open field, increased immobility in the forcedswim test, and reduced amphetamine-induced hyperactivity. Asenapine exerted no effects in the social interaction or sweet solution preference tests. The results suggest that asenapine exerts antimanic-like effects in some of the behavioral tests performed in Black Swiss mice. These data support the utilization of asenapine in the treatment of BPD.
AB - Asenapine is indicated for the treatment of schizophrenia and manic episodes in bipolar disorder (BPD). There is a paucity of information on the effects of asenapine in animal models of BPD, but such work is essential to discover its scope of effects and its mechanisms of therapeutic action. This study evaluated the effects of asenapine in a validated test battery for manic-like behaviors in Black Swiss mice. Male Black Swiss mice received asenapine at 0.03, 0.1, and 0.3 mg/kg twice daily for 7 days and were tested for spontaneous activity, sweet solution preference, forcedswim test, social interaction, and amphetamine-induced hyperactivity. Asenapine treatment resulted in dosedependent, clinically relevant plasma levels. Asenapine, at the 0.1 and 0.3 mg/kg doses, reduced activity, with the 0.3 mg/kg dose also resulting in increased time in the center of an open field, increased immobility in the forcedswim test, and reduced amphetamine-induced hyperactivity. Asenapine exerted no effects in the social interaction or sweet solution preference tests. The results suggest that asenapine exerts antimanic-like effects in some of the behavioral tests performed in Black Swiss mice. These data support the utilization of asenapine in the treatment of BPD.
KW - Black Swiss mice
KW - animal models
KW - antipsychotic
KW - bipolar disorder
KW - mania
KW - mood stabilizers
UR - http://www.scopus.com/inward/record.url?scp=84937732710&partnerID=8YFLogxK
U2 - 10.1097/FBP.0000000000000128
DO - 10.1097/FBP.0000000000000128
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25590966
AN - SCOPUS:84937732710
SN - 0955-8810
VL - 26
SP - 331
EP - 337
JO - Behavioural Pharmacology
JF - Behavioural Pharmacology
IS - 4
ER -